Despite the success of ARVs in suppressing HIV, drug toxicity remains an area of concern. Older ARV classes, such as NRTI and PI, can deplete mitochondrial DNA (mtDNA), affect mitochondrial function, and increase mitochondrial reactive oxygen species (mtROS). These effects may be mitigated by human telomerase reverse transcriptase (hTERT), which can translocate to mitochondria, where it provides protection from ROS-induced damage. Newer integrase strand transfer inhibitors (InSTIs), such as Dolutegravir (DTG) and Raltegravir (RAL), show excellent clinical tolerance. However, there is emerging evidence of possible off-target effects, such a weight gain, with potential mitochondrial etiology given their role in metabolism. Our objective was to evaluate cellular and mitochondrial toxicities of first line InSTI-containing ARV regimens and determine whether hTERT has a protective effect.
Telomerase-independent SV40-transformed human lung fibroblasts (WI-38 VA13) were transduced to express hTERT with and without its mitochondrial targeting signal (MTS). Three isogenic cell lines (–hTERT, +hTERT–MTS, and +hTERT) were exposed to seven distinct (NNRTI, PI, or InSTI-based) ARV regimens at pharmacological concentrations (1X Cmax) for nine days, followed by recovery in drug-free media for six days. n=6 independent sets. After both treatment and recovery, mitochondrial mass, intermembrane potential, ROS, and cellular apoptosis were quantified using flow cytometry. Mitochondrial images were captured by fluorescence microscopy and the recently developed neural network analysis tool MitoSegNet, was used to quantify differences in mitochondrial morphology.
Cells exposed to DTG-containing regimens had increased apoptosis, mtROS, and mitochondrial mass, compared to both 0.1% DMSO controls (all p?0.034) and non-DTG (including RAL)- containing regimens (all p<0.001). DTG exposure increased mitochondrial area, perimeter, eccentricity, branch number and length compared to non-DTG regimens (all p?0.005). Although hTERT may mitigate some PI-induced effects, it did not protect against DTG. All observed alterations were reversed upon ARV removal.
Taken together, our findings suggest that DTG-containing regimens induce mitochondrial toxicity and fragmentation of mitochondrial networks, something not seen with RAL. Given that HIV treatment is life-long and the global use of DTG, further investigations are warranted to understand the mechanisms and long-term effects of these toxicities.